<PAGE> 1
SCHEDULE 13D
(RULE 13d-101)
Information to be Included in Statements Filed Pursuant to Rule 13d-1(a) and
Amendments Thereto Filed Pursuant to Rule 13d-2(a)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
King Pharmaceuticals, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, without par value
--------------------------------------------------------------------------------
(Title of Class of Securities)
49558210-8
--------------------------------------------------------------------------------
(CUSIP Number)
Charles E.H. Luedde, Esq.
10 South Broadway, Suite 2000, St. Louis, Missouri 63102 (314) 241-9090
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
November 7, 2000
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the
following box / /.
Note: Schedules filed in paper format shall include a signed original
and five copies of the schedule, including all exhibits. See Rule
13d-7(b) for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE> 2
CUSIP NO. 13D PAGE 2 OF 4 PAGES
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
(ENTITIES ONLY)
Dennis M. Jones; Judith A. Jones
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(See Instructions)
(a) [x]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS (See Instructions)
OO
--------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(d) OR 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF
7,365,111
SHARES -----------------------------------------------------------------
8 SHARED VOTING POWER
BENEFICIALLY
-0-
OWNED BY EACH -----------------------------------------------------------------
9 SOLE DISPOSITIVE POWER
REPORTING
7,365,111
PERSON -----------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
WITH
-0-
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES (See Instructions) [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.3%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (See Instructions)
IN
--------------------------------------------------------------------------------
<PAGE> 3
--------------------------------------------------------------------------------
CUSIP No. 49558210-8 13D Page 3 of 4 Pages
--------------------------------------------------------------------------------
AMENDMENT NO. 1 TO SCHEDULE 13D
Dennis M. Jones and Judith A. Jones reported the acquisition of shares
of Common Stock, without par value ("Stock"), of King Pharmaceuticals, Inc., a
Delaware corporation (the "Issuer"), in an initial filing of this Schedule 13D
on September 1, 2000. The Cover Page, Page 2 and Items 4, 5 and 7 are hereby
amended as follows. All other items are unchanged from the initial filing.
ITEM 4. Purpose of the Transaction.
On November 7, 2000 Judith A. Jones sold an aggregate of 1,500,000
shares of the Stock of the Issuer, through DLJ Securities in a Rule 145
transaction in order to diversify her investment portfolio. Net proceeds per
share were $46.25.
ITEM 5. Interest in Securities of the Issuer.
(a) Dennis M. Jones and Judith A. Jones 7,365,111 shares* 4.3%**
* includes 1,708,593 shares which may be acquired upon exercise
of non-statutory options.
**percent of class is based upon: (i) 92,150,970 shares of the
Issuer's Stock issued and outstanding as of August 10, 2000
(the record date for purposes of the Jones/King Merger), plus
(ii) 73,767,854 shares of the Issuer's stock (which is
equivalent to 1.125 times the number of shares of the common
stock of Jones Pharma Incorporated issued and outstanding as of
August 10, 2000), plus (iii) the shares which may be acquired
under such non-statutory options, plus (iv) 2,700,000 shares
representing the approximate number reported by the Issuer as
sold on October 20, 2000.
(b) Although each of Mr. and Mrs. Jones individually have sole power
to vote their respective shares and sole dispositive powers, each
of them may be deemed to possess shared voting and dispositive
powers over the shares owned by the other. Each of Mr. and
Mrs. Jones have historically disclaimed economic ownership of
shares held by the other, however, the shares of both parties are
subject to the dispositive terms of the redemption agreement
described in Item 6 of this Schedule 13D as originally filed.
(c) See Item 4 above.
(d) Not applicable.
(e) As the result of the disposition of shares reflected in (c)
above, on November 7, 2000, Mr. and Mrs. Jones ceased to be the
beneficial owners of more than 5% of the outstanding Stock of the
Issuer and, accordingly, are not obligated under Section 13(d) to
report further acquisitions and sales unless such future
acquisitions (when added to remaining holdings) result in
beneficial ownership of more than 5% of the Issuer's Stock.
ITEM 7. Material to be Filed as Exhibits.
Exhibit 1: Rule 13d-1(k)(1) Joint Filing Agreement.
<PAGE> 4
--------------------------------------------------------------------------------
CUSIP No. 49558210-8 13D Page 4 of 4 Pages
--------------------------------------------------------------------------------
After reasonable inquiry, and to the best of the undersigneds'
knowledge and belief, the undersigned certify that the information set forth in
this statement is true, complete and correct.
/s/ Dennis M. Jones
-------------------------------
Dennis M. Jones
Individually and as Trustee of the Dennis M. Jones
Amended and Restated Revocable Trust dated
March 16, 1993
Date: November 7, 2000
/s/ Judith A. Jones
-------------------------------
Judith A. Jones
Individually and as Trustee of the Judith A. Jones
Amended and Restated Revocable Trust dated June
8, 1993
Date: November 7, 2000
